BNL-101 / Bionaut - LARVOL DELTA

FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients (PRNewswire) - “Bionaut Labs…announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients.”

Orphan drug • Glioma • Oncology